incretin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
| Property | Value | Notes |
|---|---|---|
| 分子类型 | 合成修饰肽 | 39 个氨基酸，含脂肪酸侧链 |
| 受体靶点 | GIP 与 GLP-1 受体 | 双重激动剂 |
| 分子量 | 约 4.8 kDa | 以游离肽计 |
| 外观 | 白色至类白色粉末 | 冻干形态常见 |
| 溶解性 | 可溶于水及水性缓冲液 | 溶解后宜低温保存 |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Together with supplemental equations (for example, conservation of mass) and well-formulated boundary conditions, the Navier–Stokes equations seem to model fluid motion accurately; even turbulent flows seem (on average) to agree with real world observations. The Navier–Stokes equations assume that the fluid being studied is a continuum (it is infinitely divisible and not composed of particles such as atoms or molecules), and is not moving at relativistic velocities. At very small scales or under extreme conditions, real fluids made out of discrete molecules will produce results different from the continuous fluids modeled by the Navier–Stokes equations. For example, capillarity of internal layers in fluids appears for flow with high gradients. For large Knudsen number of the problem, the Boltzmann equation may be a suitable replacement. Failing that, one may have to resort to molecular dynamics or various hybrid methods. Another limitation is simply the complicated nature of the equations. Time-tested formulations exist for common fluid families, but the application of the Navier–Stokes equations to less common families tends to result in very complicated formulations and often to open research problems. For this reason, these equations are usually written for Newtonian fluids where the viscosity model is linear; truly general models for the flow of other kinds of fluids (such as blood) do not exist.
North Carolina State University's College of Veterinary Medicine in Raleigh, North Carolina, uses both plastic coating (PC) and plastination (PN) to investigate and compare the difference in the two methods. The PC method was simple and inexpensive, but the PN specimens were more flexible, durable, and lifelike than those preserved by the PC method. The use of plastination allowed the use of many body parts such as muscle, nerves, bones, ligaments, and central nervous system to be preserved. The University of Texas Health Science Center at San Antonio was the first school in the United States to use this technique to prepare gross organ specimens for use in teaching. The New York University College of Dentistry, Philadelphia College of Osteopathic Medicine, University of Warwick, and University of Northumbria use collections of plastinates as teaching aids. The University of Vienna and the University of Sheffield have their own plastination laboratories. The first medical school in India to have a plastination lab was A.I.I.M.S, New Delhi with others following suit like Christian Medical College, Vellore, Government Institute of Medical Sciences, Greater Noida etc.
=== Polymer chemistry === Although MS-based analyses of polymers have largely been performed using single-stage MS, tandem MS has also been used to characterize polymer components. CID is the most common method of dissociation used, but ETD has been used as a complementary method. Unique bond cleavages resulting from ETD supply valuable diagnostic information.
=== Cordelia Hanani-Spyrka === Cordelia Hanani-Spyrka (Claire Forlani) is Yasmin's aunt and the sister of her late father Charles, working as a public relations executive. Yasmin invites her to Henry's 40th birthday, where Cordelia gushes about her relationship with a younger man, and advises Yasmin not to tie her future to Henry, warning that men invariably weaponize women's unconditional love. Yasmin later catches Cordelia performing oral sex on Otto Mostyn and confronts her afterwards, asking why she never came to Charles' funeral and whether she knew about his serial sexual predation; Cordelia dismisses her brother's behavior, arguing that both she and Charles came from a "bohemian childhood", and it is implied the two had an incestuous relationship in their youth. Before leaving, Cordelia spitefully tells Yasmin that Charles planned to terminate her before learning she would be born a girl.
Breó (meaning 'glow' in Irish) was a wheat beer; it cost around IR£5 million to develop. A brewing byproduct of Guinness, Guinness Yeast Extract (GYE), was produced until the 1950s. In the UK, a HP Guinness Sauce was manufactured by Heinz and available as of 2013. In March 2010, Guinness began test marketing Guinness Black Lager, a new black lager, in Northern Ireland and Malaysia. As of September 2010, Guinness Black Lager is no longer readily available in Malaysia. In October 2010, Guinness began selling Foreign Extra Stout in 4 packs of bottles in the United States.
Sources: en.wikipedia.org
== Gameplay == As with previous Half-Life games, Episode Two is played in the first person as Gordon Freeman against transhuman troops, known as the Combine, and other hostile alien creatures. Levels are linear but add a more open environment, consisting of puzzles and first-person shooter (FPS) gameplay. Sequences involving vehicles are interspersed throughout the game, breaking up moments of combat. One of the focal points was the increased use of vehicles in open areas. However, the game retains its original linear style until the final battle. Episode Two has more puzzles than Episode One; the sequence in which the player must cross a damaged bridge was the largest physics puzzle in the series up to that point. As in the previous two games, Episode Two features numerous "achievements" (similar to PlayStation 3's Trophies and Xbox Live's Achievements) for carrying out certain tasks. Some are essential to game progress, such as helping fight off an antlion invasion, or defeating the first Hunters. Others are optional tricks or feats the player can perform, such as killing a Combine soldier with their own grenade or running down a certain number of enemies with the car. Episode Two features a new enemy, the Hunter, which is seen briefly in a recorded message in Episode One. The Hunter is one of the most dangerous enemies and serves as means of emotional development for Alyx Vance. The Hunter is a powerful and resilient enemy which players must often run from while seeking a means to fight back; Episode Two's environments are designed with this in mind.
=== Earliest work === The study of hydrogen stable isotopes began with the discovery of deuterium by chemist Harold Urey. Even though the neutron was not realized until 1932, Urey began searching for "heavy hydrogen" in 1931. Urey and his colleague George Murphy calculated the redshift of heavy hydrogen from the Balmer series and observed very faint lines on a spectrographic study. To intensify the spectroscopic lines for publishable data, Murphy and Urey paired with Ferdinand Brickwedde and distilled a more concentrated pool of heavy hydrogen, now called deuterium. This work on hydrogen isotopes won Urey the 1934 Nobel Prize in Chemistry.
The following month an attempted coup d'état was staged by a sector of the army that sought to paralyze the democratic process and that only the decisive intervention of King Juan Carlos I managed to stop. After 23-F, the new UCD government presided by Leopoldo Calvo Sotelo managed to rule largely thanks to the support given by the PSOE and its leader Felipe González because the "self-destruction" of the UCD continued until October 1982, when new elections were held and were won overwhelmingly by the PSOE. Thus a party that had been one of the defeated parties in the civil war of 1936–1939 took power. After 1982, the democratic system was consolidated and Spain experienced a long period of political stability in which there was alternation in government between the left and the right in a peaceful manner following the dictates of the elections (the PSOE governed between 1982 and 1996 and between 2004 and 2011; the People's Party, which emerged from the "refounding" in 1989 of the Alianza Popular, between 1996 and 2004 and between 2011 and 2014). It was decisive for the achievement of political stability that the positions of the two major parties on the most important issues were not antagonistic and that there were no major "social fractures", the latter thanks to the development of the Welfare state and "social protection" policies. Also during those years, Spain actively participated in the transformation of the European Community, which it joined in 1986, in the European Union and in the establishment of the common currency, the euro.
Leukemia: diagnosis/recurrence, Biopsy;; Clinical Immunology Laboratory, Tissue lab "Aberrant cell population(phenotype); taxon;Biopsy(spec.)"; Clinical Immunology Laboratory, Tissue lab rearrangement of TCR/IgH- is. Biopsy;"Biopsy-(TCR+Igh- )-Immune rearrangement; clonality(0 1) = ?"; Clinical Immunology Laboratory, Tissue lab "Hem. Marker study, ADULTS over 16 years;Biopsy";Hem. Marker study, ADULTS over 16 years, Tissue biopsies;Hematology Marker Laboratory "Hem. Marker study, ADULTS over 16 years;Biopsy";Hem. Marker Examination, ADULTS over 16 years, Biopsy from Corpus Vitreum;Hematology Marker Laboratory Histologic examination of testis biopsy; Laboratory for Growth and Reproduction Miscellaneous analysis;DNA(spec.)-MLPA ocular melanoma; depends Miscellaneous analysis;FISH malignant melanoma choroidea; depends Helicobacter pylori (culture);Helicobacter pylori (culture); Clinical Microbiology Laboratory Tropheryma whipplei DNA/RNA;;Unknown Culture and resistance;Biopsy/tissue/bone tissue culture and resistance; Clinical Microbiology Laboratory
Sources: en.wikipedia.org
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。
分子上的脂肪酸侧链使其与血浆白蛋白结合增强，显著延长循环半衰期。半衰期延长后，稳定血药浓度可在较长的给药间隔内维持，因此常见用法为每周一次。
同时激活两条肠促胰素通路可能在胰岛素分泌、胃排空和食欲调节上产生叠加效应。与单靶点相比，临床研究中观察到的血糖与体重变化幅度通常更明显，但各通路的具体贡献比例尚无定论。
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.